Κατεύθυνση Έρευνα στην Γυναικεία ΑναπαραγωγήLibrary of the School of Health Sciences
Γεώργιος Μαστοράκος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Φλώρα Ζαγουρή, Αναπληρώτρια Καθηγήτρια , Ιατρική Σχολή ,ΕΚΠΑ
Ευαγγελία Ζαπάντη, Διευθύντρια , ΓΝΑ Αλεξάνδρα
Αναδρομική μελέτη των θυρεοειδοπαθειών στον ελληνικό πληθυσμό, ως αποτέλεσμα ανοσοθεραπείας
Retrospective study of thyroidopathies in Greek population, as result of anosotherapy
Introduction: ICPi therapy causes immune-related adverse events. Εndocrinopa-thies, such as: hypophysitis, thyroid dysfunction, insulin-deficient diabetes melli-tus, and primary adrenal insufficiency are the most common endocrine side effects. The aim of this study was to describe the progress of thyroidopathies after ICPi therapy and their treatment, as there are not any guidelines.
Methods: This study is a retrospective study and took place between 2019-2020 at Oncological department of «ALEXANDRA» hospital. The study group consisted of 31 patients, who had solid organ cancer. The sample size was divided into three categories : patients who were euthyroid before and after the ICPi therapy, those who developed thyroid dysfunction after therapy and those who had thyroidopa-thy and got worsened.
Results: Out of 31 patients, 26 had normal thyroid function before ICPi therapy. Out of those 26, 13 were euthyroid after therapy, seven developed destructive thy-roiditis. From those seven, six patients received b-blockers and 1 only received therapy with corticosteroids. The rest 6 had hypothyroidism and received replace-ment therapy with thyroxine. Out of 5 patients who had disturbed thyroid function before ICPi therapy, one patient who suffered Graves disease and received methi-mazole, showed destructive thyroiditis and received combined therapy with methi-mazole and corticosteroids. The rest 4 patients showed pre-existing hypothyroid-ism. Out of 4, one patient showed improvement in his thyroid function, two pa-tients got worse despite the thyroxine therapy and one patient showed destructive thyroiditis and received b-blockers. All of them became eythyroid after therapy. Besides, all patients who showed thyroid abnormality, had elevated titles of anti-TG and anti-TPO, but no one of TRAbs.
Conclusions: ICPi therapy can cause destructive thyroiditis and hypothyroidism, even in euthyroid patients before therapy. ICPi therapy can deteriorate significantly existing thyroid disease. Furthermore, can be associated with elevated title of anti-TG and anti-TPO, but no TRAbs. In conclusion, it is necessary to check thyroid function before, during and after ICPi therapy.
Main subject category:
ICPi therapy, Hypothyroidism, Destructive thyroiditis, Anti-tg anti-tpo, Trabs, Thyroxine, b-blockers, Corticosteroids
Kontou Paraskevi MSc.pdf
File access is restricted only to the intranet of UoA.